Saturn Clinical Trial
Are you eligible to
participate?
Answer these questions to find out.
Are you eligible to
participate?
Answer these questions to find out.
Is there a clinical trial
location near me?
Find a participating location
using our Clinical Trial Locator.
Read more about the
Phase 2 survival results in the
Journal of Clinical Oncology
Learn more about the AFFINITY
Clinical Trial objectives and
eligibility criteria.
Do you have a question about the AFFINITY clinical trial? An AFFINITY representative is available to answer your questions.
Know someone who might be interested
in the Prostate Cancer AFFINITY Clinical
Trial? Print this Fact Sheet to share with
a family member or friend.

Send to a Friend

Fill out the form below to send an email with this website link to your friends.

*Required fields
*Your friend’s email address (enter at least one)
We will not add your recepients’ email addresses to any mailing lists or retain them for any other purposes.
1)
2)
3)
4)
5)

Message

Below is a preview of the email your friend(s) will be receiving.
Subject: [Your name] thought you'd be interested
Body: I recently visited www.ProstateCancerStudy.com and thought you would be interested in learning more about the AFFINITY Clinical Trial.
Click here to view the page or paste www.ProstateCancerStudy.com into your web browser.
Clicking the "SEND" button signifies that you have read and agree to our Privacy Policy. AFFINITY Clinical Trial respects your right to have your personal information kept private. We will not share the information you provide with any third parties or outside mailing lists.

Disclaimer: Custirsen (OGX-011) is not approved for commercial use in the United States or in countries outside of the United States. Custirsen is an investigational new drug that is being studied for the treatment of prostate cancer in clinical trials.

Taxotere® and Jevtana® are registered trademarks of Sanofi-aventis.

Taxotere® and Jevtana® are registered trademarks of Sanofi-aventis.

Taxotere® is a registered trademark of Sanofi-aventis.

Tylenol® #3 with codeine is a registered trademark of McNeil Consumer Healthcare.

*Most prostate cancer initially responds to various therapies, but eventually becomes resistant and often spreads to other parts of the body.

You are now leaving www.ProstateCancerStudy.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. We encourage you to read the privacy policy of every website
you visit.

Click "Continue" to proceed or "Return" to return to ProstateCancerStudy.com.

Continue Return

Your browser is out of date. For the best experience using this website, please upgrade your web browser.

Close

Request a call

If you have any questions about the Prostate Cancer AFFINITY Clinical Trial, please complete this form to request a call from a Clinical Trial Specialist.

Please provide information for the highlighted fields below.

An error occurred while processing this form. Please try resubmitting later.

Your first name
Your last name
Your phone number
Best times to call you


The call center is open from 5 am to 5 pm PST.
Your time zone
-->